Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
mallinckrodt.com

See what CB Insights has to offer

Investments

2

Partners & Customers

10

About Mallinckrodt

Mallinckrodt, the pharmaceuticals business of Covidien, provides products used in diagnostic procedures and in the treatment of pain and related conditions.The company is a supplier of prescription opioid pain medications and a manufacturer of active pharmaceutical ingredients. It is also a US supplier of the medical isotope technetium-99m and an industry provider in radiopharmaceuticals and contrast media and delivery systems.

Mallinckrodt Headquarter Location

3 Lotus Park The Causeway, Staines-Upon-Thames

Surrey, England, TW18 3AG,

United Kingdom

+44-017-8463-6700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mallinckrodt

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Mallinckrodt in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

M

Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Latest Mallinckrodt News

07:08 EDT MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE

Aug 3, 2022

News provided by Share this article Share this article DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Directly via the webcast link (live and replay): ABOUT MALLINCKRODT  Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com . Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. CONTACTS

Mallinckrodt Investments

2 Investments

Mallinckrodt has made 2 investments. Their latest investment was in Silence Therapeutics as part of their Corporate Minority - P2P on July 7, 2019.

CBI Logo

Mallinckrodt Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/18/2019

Corporate Minority - P2P

Silence Therapeutics

$5M

Yes

1

10/14/2016

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/18/2019

10/14/2016

Round

Corporate Minority - P2P

Grant

Company

Silence Therapeutics

Subscribe to see more

Amount

$5M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

Mallinckrodt Acquisitions

10 Acquisitions

Mallinckrodt acquired 10 companies. Their latest acquisition was Sucampo Pharmaceuticals on February 14, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/14/2018

$99M

Acq - P2P

3

12/12/2017

Series C

$99M

$62M

Acq - P2P

3

8/4/2017

Convertible Note

$99M

$86.23M

Acquired

2

8/10/2016

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/18/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/14/2018

12/12/2017

8/4/2017

8/10/2016

12/18/2015

Investment Stage

Series C

Convertible Note

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$62M

$86.23M

$99M

Note

Acq - P2P

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

3

3

2

10

10

Mallinckrodt Partners & Customers

10 Partners and customers

Mallinckrodt has 10 strategic partners and customers. Mallinckrodt recently partnered with Silence Therapeutics on February 2, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

2/26/2021

Partner

United Kingdom

Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target

Silence Therapeutics PLC said it will receive US$ 2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt .

1

7/18/2019

Licensor

United Kingdom

Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi...

STAINES-UPON-THAMES , United Kingdom and LONDON , July 18 , 2019 / PRNewswire / -- Mallinckrodt plc , a global biopharmaceutical company , and Silence Therapeutics plc , a leader in the discovery , development and delivery of novel RNA2 interference therapeutics for the treatment of serious diseases , today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ` silence ' the complement cascade , a group of proteins that are involved in the immune system and that play a role in the development of inflammation .

3

5/7/2019

Partner

United States

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial...

TUCSON , Ariz. and STAINES-UPON-THAMES , United Kingdom , May 7 , 2019 / PRNewswire / -- Cancer Prevention Pharmaceuticals , Inc. , a private biotech company developing novel therapeutics to prevent cancer and other diseases , and its partner Mallinckrodt Plc , a leading global specialty pharmaceutical company , today announced that Cancer Prevention Pharmaceuticals , Inc. 's pivotal phase 3 clinical trial , Cancer Prevention Pharmaceuticals , Inc. , of the investigational drug Cancer Prevention Pharmaceuticals , Inc. / sulindac in patients with familial adenomatous polyposis , did not meet its primary endpoint .

1

2/25/2019

Partner

Germany

Subscribe to see more

Subscribe to see more

10

2/20/2019

Licensor

Canada

Subscribe to see more

Subscribe to see more

10

Date

2/26/2021

7/18/2019

5/7/2019

2/25/2019

2/20/2019

Type

Partner

Licensor

Partner

Partner

Licensor

Business Partner

Country

United Kingdom

United Kingdom

United States

Germany

Canada

News Snippet

Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target

Silence Therapeutics PLC said it will receive US$ 2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt .

Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi...

STAINES-UPON-THAMES , United Kingdom and LONDON , July 18 , 2019 / PRNewswire / -- Mallinckrodt plc , a global biopharmaceutical company , and Silence Therapeutics plc , a leader in the discovery , development and delivery of novel RNA2 interference therapeutics for the treatment of serious diseases , today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ` silence ' the complement cascade , a group of proteins that are involved in the immune system and that play a role in the development of inflammation .

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial...

TUCSON , Ariz. and STAINES-UPON-THAMES , United Kingdom , May 7 , 2019 / PRNewswire / -- Cancer Prevention Pharmaceuticals , Inc. , a private biotech company developing novel therapeutics to prevent cancer and other diseases , and its partner Mallinckrodt Plc , a leading global specialty pharmaceutical company , today announced that Cancer Prevention Pharmaceuticals , Inc. 's pivotal phase 3 clinical trial , Cancer Prevention Pharmaceuticals , Inc. , of the investigational drug Cancer Prevention Pharmaceuticals , Inc. / sulindac in patients with familial adenomatous polyposis , did not meet its primary endpoint .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Mallinckrodt Team

10 Team Members

Mallinckrodt has 10 team members, including current Executive Vice President, Steve Romano.

Name

Work History

Title

Status

Steve Romano

Executive Vice President

Current

Joshua M. Schafe

Senior Vice President

Current

Steve Carchedi

President

Former

Bob Moussa

President

Former

George Kegler

Chief Financial Officer

Former

Name

Steve Romano

Joshua M. Schafe

Steve Carchedi

Bob Moussa

George Kegler

Work History

Title

Executive Vice President

Senior Vice President

President

President

Chief Financial Officer

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.